Healthcare Jul 07, 2021 02:58 PM (GMT+8) · EqualOcean
EUROHEALTH learned on July 7 that parexel announced on July 2 that it had reached a final merger agreement. According to the agreement, EQT IX Fund ("EQT private equity fund") and private equity investment department of Goldman Sachs asset management company ("Goldman Sachs") will spend US $8.5 billion to complete the acquisition of JINGDING pharmaceutical equity held by Pamplona Capital Management LP. It is reported that JINGDING pharmaceutical is a multinational clinical research organization (CRO) committed to developing and providing innovative therapies to improve human health. It mainly provides services to life science and biopharmaceutical customers all over the world to help them transform scientific research achievements into new therapeutic methods, including meeting customers' real-world evidence, decentralized clinical trials, clinical trials, clinical trials, and so on The demand of innovative areas such as biostatistics and data management, as well as customers' needs in key regions such as Asia Pacific, where JINGDING pharmaceutical is one of the largest and longest serving cros. Regarding the acquisition, Jamie MacDonald, chief executive of JINGDING pharmaceutical, said: "in the past 18 months, JINGDING pharmaceutical has continued its strong business growth momentum. The company's patient centered clinical trial operation accelerates the development and marketing of innovative drugs. It is estimated that the outsourcing clinical research service market will grow at a conservative compound annual growth rate of 8% - 9% in the future, so our future focus will still be growth and innovation. EQT and Goldman are very supportive of this vision. "